Sponsors (4)
The bill improves visibility, planning, and short‑term access to compounded drugs during shortages (and clarifies some compounding rules), but it raises patient safety risks, administrative burdens, and economic incentives that could complicate supply restoration and increase costs.
Hospitals, health systems, and patients (especially those with chronic or life‑saving needs) gain faster and expanded access to compounded drugs during recent shortages because prescribers and compounding/outsourcing facilities can supply limited quantities without individual patient prescriptions and more monographs are allowed for use.
Patients, providers, and the health system receive earlier visibility of supply stress because manufacturers must report demand 'surges' and APIs, enabling FDA and clinicians to plan and respond sooner to reduce or mitigate shortages.
Urgent-use compounding is subject to patient tracking and adverse‑event reporting requirements, improving post‑market safety monitoring for compounded products used during shortages.
Patients (including Medicare and Medicaid beneficiaries) face increased safety risks because non‑patient‑specific compounded products and broader allowable monographs can vary from commercial formulations and may be subject to less rigorous review.
Hospitals, prescribers, and compounding facilities will face new administrative and compliance burdens (documentation of attempts to obtain 503B products, patient IDs, reporting timelines, labeling changes, USP beyond‑use dating, MedWatch reporting) that will consume staff time and raise operating costs.
Expanding compounding exceptions during shortages and allowing broader use of bulk substances could weaken manufacturers' incentives to resume or scale commercial production, potentially prolonging some shortages.
Based on analysis of 5 sections of legislative text.
Creates a temporary urgent compounding pathway during shortages, expands manufacturer surge reporting, tightens outsourcing bulk rules, and mandates specific compounded-drug labeling and documentation.
Introduced September 11, 2025 by Diana Harshbarger · Last progress September 11, 2025
Creates a limited emergency pathway allowing licensed pharmacists or physicians to compound and deliver small amounts of drug product to a licensed prescriber for urgent in-hospital or clinical use when the drug was on the FDA shortage list recently and the prescriber certifies no equivalent 503B product is available. It also expands manufacturer reporting to FDA to include sudden surges in demand, narrows and clarifies some outsourcing- and bulk-substance rules, requires annual federal publication about bulk-substance evaluations, and imposes a new mandatory label statement for compounded drugs.